Álvarez GY, Bohorques RR, Vega PD, Noa FL

Language: Spanish
References: 14
Page:
PDF size: 367.48 Kb.

ABSTRACT

Introduction: Cardiovascular diseases are a frequent problem in patients with chronic renal failure (CRF) on dialysis. Objective: To identify the cardiovascular diseases in patients included in the Home Peritoneal Dialysis Program at the Institute of Nephrology and its possible link with the level of hydration. Method: Observational, descriptive, cross-sectional research on patients between January 2013 and May 2016, who underwent echocardiography and spectroscopic bioimpedance. Results: A total of 41 patients were researched, 56.1% were males, with average age between 50 and 64 years old (34.1%). The most frequent echocardiographic diseases were cardiac valve diseases (21.3%), changes in the diastolic function (18.1%) and ventricular hypertrophy (14.9%), found in overhydrated patients. Conclusions: Valve diseases, changes in diastolic function and ventricular hypertrophy are the most frequent cardiovascular diseases in patients with Home Peritoneal Dialysis and are related to the level of hydration.

REFERENCES

1. Alonso J, Regidor E, Barrio G. Valores poblacionales de referencia de la versión española del Cuestionario de Salud SF-36. Med Clin 1998; 111:410-416.

2. Secretaría de Salud. Estadística de egresos hospitalarios del sector público del Sistema Nacional de Salud. Salud Pública Méx. 2012; 45(4):310-327.

3. Coles G. What is the place of peritoneal dialysis in the integrated treatment of renal failure? Kidney Int. 1998; 54 : 2234-2240

4. Boerrigter G, Burnett J. C. Cardiorenal Syndrome in Descompensated Heart Failure: Prognostic and Therapeutic Implications. Current Heart Failure Reports 2004; I: 113-120.

5. Herzog J. Z, Collins A. J. Poor long-term survival after acute myocardial infarction among patient on long-term dialysis. N Engl J Med 1998; 339:799-805.

6. Neves M, Machado S. Cardiovascular risk in peritoneal dialysis. A Portuguese multicenter study. Nefrología 2014;34(2):205-11

7. Santamaría R, Gorostipedi M. Síndrome cardiorrenal. Clin Nephrol. 2013; 1- 14.

8. Ronco C, McCullough P, Anker SD. Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative. Eur Heart J. 2010; 31: 703-711.

9. Parikh N. I, Hwang S. J, Larson M. G, Meigs J. B, Levy D, Fox C. S. Cardiovascular disease risk factors in chronic kidney disease: Overall burden and rates of treatment and control. Arch Intern Med 2006; 166:1884-91.

10. Sarnak M. J, Levey A. S, Schoolwerth A. C, Coresh J, Culleton B, Hamm L, et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108:2154-69.

11. Rodríguez L. Factores de riesgo y complicaciones cardiovasculares en los pacientes bajo diálisis peritoneal. Revista Cubana de Medicina Intensiva y Emergencias 2005; 4(1).

12. Marín, Goicoechea, M. Guía de la Sociedad Española de Nefrología sobre riñón y enfermedad cardiovascular. Nefrología. 2006; Vol 26. Número 1.

13. Ito S, Higuchi Y, Yagi Y. Reduction of indoxyl sulfate by AST-120 attenuates monocyte inflammation related to chronic kidney disease. J Leukoc Biol. 2013; 93: 837-845.

14. Armstrong E, Granick JL, Simon S. Monocyte activation by uremic toxins in cardiorenal syndrome. Editorial: A missing link. J Leukoc Biol. 2013; 93: 821-823.